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Summary 
Reactivating HIV latency and then simultaneously eliminating it by antiretroviral therapy 
has become a leading strategy in curing HIV. Recently, single-cell screening experiments 
have shown the drug synergy between two categories of biomolecules, Activators (AC) 
and Noise Enhancers (NE): NE can amplify the reactivation of latent HIV induced by AC, 
although NE itself cannot reactivate HIV latency. Based on an established LTR-two-state 
effective model, we uncover two necessary conditions for this type of drug synergy: The 
decreasing of the turning-on rate of LTR induced by NE is highly inhibited when 
presented with AC; The timescale of LTR turning off without AC/NE presented should be 
no slower than the timescale of Tat transactivation. Then we propose a detailed LTR-
four-state mechanistic model with both AC/NE regulation kinetics and Tat transactivation 
circuit. We show that, in order to achieve drug synergy, the system of HIV gene state 
transition must operate out of thermodynamic equilibrium, which is caused by energy 
input. The direction of energy input determines whether the inhibition of NE upon the 
reactivation rate of LTR-off states (unbinding of RNAP) can be successfully prevented in 
the presence of AC. The drug synergy can also be significantly enhanced if the energy 
input is appropriately distributed to more than one reaction. Our model reveals a generic 
nonequilibrium mechanism underpinning the noise enhanced drug synergy, which may 
be applicable to identifying the same drug synergy on reactivating a diverse class of 
lentivirus latency. 
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Significance Statement 
The “kick and kill” strategy has become a promising way to cure HIV by eliminating latent 
HIV reservoirs, the main barrier to a clinical cure. Two categories of biomolecules, 
Activators (AC) and Noise Enhancers (NE), have been found to have synergy on 
reactivating latent HIV (kick strategy). We uncover the underlying non-equilibrium 
mechanism of such drug synergy by developing mathematical models based on genetic 
regulatory kinetics. We find that controlling the magnitude and direction of energy input 
into genetic regulatory kinetics can prevent NE from reducing the turn-on rate of the 
inactivated gene state in the presence of AC, which produces the synergy. This general 
nonequilibrium mechanism can be useful for identifying other drug synergies on lentivirus 
latency reactivation.
Introduction:  
At the end of 2017, more than 36 million people were estimated to be infected 
with HIV (1).  After HIV infects CD4+ cells, it can replicate or enter proviral 
latency (Figure 1A). Latent HIV reservoirs are the main obstacle to achieving 
a clinical cure (2). Reactivating latent HIV, quickly followed by antiretroviral 
therapy, has become a promising way to cure HIV-infected patients (3). 
Recently, synergistic combinations of noise enhancers and activators drugs 
were reported to beat other reactivation cocktails in reactivating HIV latency, 
yet induced less cytotoxicity (4). Two specific types of drugs used in (4): 
Activators (AC), a small biological molecule that increases the average 
expression level of HIV proteins, and Noise Enhancers (NE), a different type 
of molecule that increases the noise of HIV protein expression but does not 
affect the average expression level. While NE itself cannot reactivate latent 
HIV, it was shown to amplify AC-induced reactivation of HIV significantly (4). 
The synergy from adding NE with AC to latent HIV is shown in Figure 1B. 
However, the biomolecular mechanisms underlying the synergy between AC 
and NE have not been fully resolved. 
The main ingredients of the HIV regulatory loop are the promoter long 
terminal repeats (LTR) and the Tat transactivation on LTR. LTR is the 
promoter of the HIV genome and has a larger expression noise than 
promoters of human genes (5, 6). Nucleosomes associated with the LTR 
often block the full transcription by RNA polymerase (RNAP), resulting in a 
low basal expression rate. The rarely produced Tat protein complexes with 
CDK9 and CyclinT1 to form the positive transcriptional elongation factor b 
(pTEFb). pTEFb can bind to the transactivation response element (TAR) on 
the initially transcribed part of the HIV mRNA and remodel downstream 
nucleosomes. This remodeling assists the elongation of the mRNA, thus 
forming positive feedback (7-9). In addition, a bimodal gene expression 
(“phenotypic bifurcation” (10)) pattern was found in the offspring of defective-
HIV infected cells with initially intermediate expression (10). However, it was 
reported that the cooperativity coefficient (Hill coefficient) of Tat is only one 
(11), which means that the mean-field deterministic dynamics of HIV gene 
expression is monostable. This is distinct from the genetic toggle switch of the 
lambda phage regulatory loop with stronger feedback and bi-stable 
deterministic dynamics (12), or an oscillatory network with negative feedback 
and a limit cycle (13). The deterministic dynamics of the HIV regulatory 
network is insufficient to explain the observed bimodality, and a stochastic 
description may be required. By combining the bimodality and noisiness of 
HIV promoter gene expression, Weinberger et al. found that the bimodality 
arises from a very slow rate of switching on LTR expression (10), resulting in 
a much noisier dynamics than those observed for normal human promoters. 
On the other hand, functions of certain Activators and Noise Enhancers are 
partially known. For example, as Activators, TNF and prostratin can activate 
the transcriptional factor NF-κB, and therefore antagonize HIV latency(14-16). 
Some of these Noise Enhancers, such as ethinyl estradiol, can influence HIV 
expression through another transcriptional factor SP1 or the structural state of 
chromatin (17, 18). The molecular mechanisms of most noise enhancers are 
still unclear, indicating the complicated regulation mechanism of HIV 
dynamics. However, no matter how complex it is, what these activators or 
noise enhancers regulated are just the rates between different gene/promoter 
states described by TF binding or structural difference. Therefore, the 
functions of Activators and Noise Enhancers can be analyzed by certain 
minimal but general models. 
Thermodynamic energy dissipation plays a crucial role in bioactivities and 
bioreactions. General model considering the binding of multiple transcription 
factors (TF) under thermodynamic equilibrium in prokaryotic cells and the 
function that different pair TF interactions can achieve in gene expression of 
cells was already studied extensively (19, 20). However, in studies of 
eukaryotic transcriptional dynamics, a non-equilibrium mechanism is found 
necessary(21), and many far-from-equilibrium models have been proposed 
(22-25). In addition to biomolecule synthesis and cell motility, the regulatory 
function of a living cell, such as adaptation and precise control of oscillations 
was also found highly dissipative (26, 27). Hence, we are very curious about 
whether certain energy input is necessary for this type of drug synergy. 
In addition, in a self-positive-feedback gene regulatory network, the timescale 
of DNA state transition, mRNA transcription, mRNA decay, protein translation, 
and protein decay, will influence the cell fate landscape and phenotype 
transitions (28-30). Post-integration HIV gene expression is one example 
system of the TF regulatory mechanism of gene expression with self-positive-
feedback. Hence, we are also interested in how the timescales of gene-state 
transition and protein dynamics influence the drug synergy.  
In this essay, we first investigate an established LTR-two-state model and find 
two necessary conditions for the synergy between AC and NE on reactivating 
latently infected HIV: (i) AC inhibits NE’s function of reducing the transition 
rate 𝑘୭୬ for the gene-state reactivation; (ii) the rate 𝑘୭୤୤ for the promoter to turn 
off is not slower than the rate for Tat transactivation when the promoter is 
already turned on. We then propose an LTR-four-state model and prove that 
the noise enhanced drug synergy is indeed a non-equilibrium phenomenon of 
the regulation of HIV promoter LTR. We show that controlling the magnitude 
and direction of the system energy input can deter NE from reducing the 
turned-on rate of inactivated gene state in the presence of AC, which induces 
the synergy between AC and NE on the LTR transcription. The drug synergy 
can be significantly enhanced when we distribute the total energy input into 
two specific different reactions. Moreover, we show that in the Tat self-
positive-feedback HIV system, the synergy of AC and NE on the transcription 
at genetic level can pass to the translation at protein level, only if the 
timescale of DNA unbinding RNAP (𝑘୭୤୤ or 𝑘୳୬ୠ୧୬ୢ୮) is not slower than the 
timescale of Tat transactivation at gene activated state.  
Materials and methods 
To investigate the synergy between AC and NE, we first employ a well-
established LTR-two-state model with Tat transactivation from the previous 
study (Figure 2A) (4, 31). In this model, LTR (the promoter of HIV) has two 
states: on state and off state. LTR can transit to the transcriptionally inactive 
state LTR-off at rate 𝑘୭୤୤ and transit to the transcriptionally active state LTR-on 
at rate 𝑘୭୬. Tat can transactivate LTR-on state promoting a higher 
transcription rate 𝑘୲୰ୟ୬ୱୟୡ୲ than the basal transcription rate 𝑘୫ due to Tat’s 
enhancing LTR transcriptional elongation (See Supplementary Section 1.1 for 
more details). The values of parameters (𝑘୭୬, 𝑘୭୤୤, 𝑘୲୰ୟ୬ୱୟୡ୲) are the same as 
those in (31), which is quantified by single-cell analysis (32-34).  
As assumed in (4), adding only AC to the system increases 𝑘୭୬, while adding 
only NE reduces 𝑘୭୬ and 𝑘୭୤୤ simultaneously with their ratio fixed. We use 
parameter 𝑓୧୬୦ to quantify the degree of AC’s inhibition upon the NE-induced 
reduction of 𝑘୭୬, which is defined as  
𝑓୧୬୦ ൌ ln൫𝑘୭୬,୅େ,୒୉൯ െ ln൫𝑘୭୬,୅େ൯ln൫𝑘୭୤୤,୅େ൯ െ ln൫𝑘୭୤୤,୅େ,୒୉൯ ൅ 1 
(See Supplementary Section 1.2-1.3 for more details).  𝑓୧୬୦ ൌ 0 represents AC 
does not inhibit NE’s function of reducing 𝑘୭୬ (Figure S1C, left panel), and 
𝑓୧୬୦ ൐ 0 means that AC inhibits NE’s function of reducing 𝑘୭୬. Particularly, 
𝑓୧୬୦ ൌ 1 means that NE’s function of reducing 𝑘୭୬ is fully inhibited by AC 
(Figure S1C, right panel). 
We propose a more detailed LTR-four-state model with both transcript 
activation and Tat transactivation (Figure 3A, Figure S2A). As the HIV 
promoter, LTR controls HIV protein expression after the HIV genome 
integrates into the DNA of human CD4+ cells (35, 36). In this model, there are 
four different promoter states: LTR state is the free state; LTR* is the 
activated state but without RNAP binding; LTR-P and LTR*-P are the 
corresponding RNAP-bounded states. AC is assumed to promote LTR 
transiting to the activated state LTR*, e.g., LTR bound with NF-κB, and LTR* 
recruits RNA polymerase much easier than LTR itself, e.g., the NF-κB bound 
to LTR acting as a Transcription Factor (TF) to recruit RNA polymerase 
(RNAP) to LTR (37). Dar, Hosmane, Arkin, Siliciano and Weinberger (4) show 
that the screened Noise Enhancers have no effect on post transcription. 
Some NEs can increase transcription factors in cells, such as SP1 (17, 18). 
Similar to (4), we assume that NE can slow down the switching rates between 
LTR and LTR-P. 
We use the Markov jumping process to model the transition among LTR 
states with AC and/or NE added (Figure 3A). The four states can mutually 
transit: in the absence of AC, RNAP binds to LTR at a relatively slow rate 
𝑘ୠ୧୬ୢ୮ሾ𝑃ሿ and unbinds at a relatively fast rate 𝑘୳୬ୠ୧୬ୢ୮; LTR transit to LTR* 
state at an extremely slow rate 𝑘ୟୡ୲ without AC, but at a much higher rate 
𝑘ୟୡ୲𝛾 (𝛾 ≫ 1)  with AC presented; RNAP is recruited to LTR* at a higher rate 
𝜔𝑘ୠ୧୬ୢ୮, where 𝜔 is the attraction coefficient (𝜔 ൐ 1); when NE (or Noise 
Suppressor, NS) is added, LTR will bind and unbind RNAP at slower (faster 
for NS) rates (𝑘ୠ୧୬ୢ୮𝑒ିఈ, 𝑘୳୬ୠ୧୬ୢ୮𝑒ିఈ) with noise attenuation factor  𝛼. Note 
that the setup of the model showed in Figure 3A is under the assumption of 
the detailed balance. We will analyze both the models with or without this 
assumption in the following sections.  
We also combine the LTR-four-state model with the transcription/translation 
module without Tat transactivation to characterize the procedure of screening 
AC and NE (Figure 3B). In screening experiments of AC and NE, the LTR-
GFP vectors without Tat transactivation were used (4). For the LTR-GFP 
vectors, with RNAP bond to LTR (i.e., LTR-P state or LTR*-P state), the 
downstream DNA of LTR can be transcribed into mRNA at rate 𝑘୫, 
independent of the GFP copy number. Then the mRNA can be translated into 
protein at rate 𝑘ୋ୊୔. Also, mRNA and GFP will degrade at rate 𝑑୫ and 𝑑ୋ୊୔, 
respectively (Figure 3B).  
In the experiments of testing the synergy between AC and NE on HIV latency 
reactivation, the full-length HIV with Tat transactivation was used to infect host 
cells instead of the LTR-GFP vector (4). For the full-length HIV vector, the Tat 
protein expressed by the HIV genome enhances transcriptional elongation by 
mediating RNAP hyperphosphorylation and thus transactivates the LTR 
promoter (38-40).  
Based on the biological evidence and previous models(31, 41), we construct 
the Tat transactivation module (Figure 3C; see Supplementary Section 2.4 for 
details). Only at LTR-on states (LTR-P and LTR*-P), HIV genome can be 
transcribed into mRNA, and Tat transactivates LTR-on states in a Hill 
equation form:  
𝑘୫ ൌ 𝑘୫ୠୟୱୟ୪ ൅ 𝑘୲୰ୱଵ
𝑇𝑎𝑡
𝑘୲୰ୱଶ
1 ൅ 𝑇𝑎𝑡𝑘୲୰ୱଶ
 
In addition, previous experiments also certified that Tat transactivation could 
stabilize HIV activation state autonomous from the host cellular state (31, 34). 
Based on this, we assume that Tat reduces the dissociating rate of RNAP 
from LTR, 𝑘௨௡௕௜௡ௗ௣, thereby stabilizing the HIV activation state (Figure 3C 
inset) (See Supplementary Section 2.4 and 2.12 for details and parameter 
value)  
𝑘୳୬ୠ୧୬ୢ୮ ൌ 𝐾୲୦୰ୣୱ୦୭୪ୢ
ଷ ൅ 𝛿𝑇𝑎𝑡ଷ
𝐾୲୦୰ୣୱ୦୭୪ୢଷ ൅ 𝑇𝑎𝑡ଷ 𝑘୳୬ୠ୧୬ୢ୮଴ 
Then in the following sections, we use the LTR-four-state model coupled with 
Tat transactivation module to investigate how LTR expression and HIV fates 
are regulated by NE and AC under the Tat transactivation. We also simulate 
HIV expression trajectories in host T-cell from HIV latent initial state and 
calculate the percentage of cells expressing HIV protein reached a threshold 
(#Tat = 75) after a certain time (100 hours) as the reactivation ratio (Figure 
S2C; see Supplementary Section 2.7 for more details).   
Results 
The LTR-two-state model with significant large 𝒌𝒐𝒇𝒇 can exhibit drug 
synergy between NE and AC 
We simulate the LTR-two-state model showed in Figure 2A using Stochastic 
Simulation Algorithm (SSA) (42), calculating the reactivation of HIV latently 
infected T cells after adding NE and/or AC, with the above assumptions on 
AC’s and NE’s functions.  
Through simulation, we find that AC’s inhibiting NE’s function on 𝑘୭୬ is 
necessary for the synergy between AC and NE (Figure 2C-D). When AC has 
no inhibiting effect on NE, corresponding to 𝑓୧୬୦ ൌ 0, there is no synergy 
between AC and NE in the whole reasonable parameter space (Figure 2C, 
Figure 2B black arrow). Only when AC inhibits NE’s function of reducing 𝑘୭୬, 
there can be synergy between AC and NE on reactivating latent HIV (Figure 
2D, Figure 2B red arrow). 
We also find out that another necessary condition for NE having synergy with 
AC is 𝑘୭୤୤ being greater than 10ିଶ hourିଵ , which is larger than the 
parameters used in previous studies (31). However, other important results 
shown in previous literature, the bimodal distribution of phenotype bifurcation 
(10) and HIV latency establishment operating autonomously from the host 
cellular state (31), are not sensitive to the increasing of 𝑘୭୤୤ (Figure S1G-I). 
When 𝑘୭୤୤ is no greater than 10ିଶ, there is no synergy between AC and NE on 
reactivating latent HIV (Figure 2E; Figure S1E). However, if 𝑘୭୤୤ is greater 
than 10ିଶ, then NE can have synergy with AC on reactivating latent HIV 
(Figure 2F-G; Figure S1F). Furthermore, the synergy between AC and NE will 
increase with the inhibiting effect quantity 𝑓୧୬୦ ൐ 0 only when 𝑘୭୤୤ is sufficiently 
large, such as 𝑘୭୤୤ ൌ 0.8 ൐ 10ିଶ (red line in Figure 2G). There will be no 
synergy between AC and NE with the inhibiting effect quantity 𝑓୧୬୦ ൐ 0 if 𝑘୭୤୤ ൏
10ିଶ(red line in Figure 2E). Actually, in a latent HIV system, 𝑘୭୤୤ is more likely 
to be larger than that previously used in literature. Direct sequencing of HIV 
integration sites showed that latent HIV frequently integrated into 
heterochromatin (38). The transcription is continuously turned off in 
heterochromatin, a tightly packed form of DNA (43). Thus, in latent HIV, LTR 
transcription-permissive state should be unstable, corresponding to larger 𝑘୭୤୤, 
as one characteristic of the HIV integrating into heterochromatin.  
In summary, we find two necessary conditions of drug synergy from our 
simulation results: (i) AC inhibits NE’s function of reducing 𝑘୭୬; (ii) sufficiently 
large 𝑘୭୤୤ (rate of LTR turning off or unbinding RNAP). However, this LTR-two-
state model is oversimplified. We still do not know much about what causes 
AC inhibiting NE’s function of reducing 𝑘୭୬ (the assumption made in (4)) and 
why NE synergizes with AC only if 𝑘୭୤୤ is large. 
No drug synergy can be produced under the detailed balance condition 
in the LTR-four-state model coupling with Tat transactivation 
Under the detailed balance condition (Figure 3A), our LTR-four-state model 
with the transcription/translation module without Tat transactivation (Figure 
3B) illustrates that AC increases LTR mean expression level and that NE 
increases LTR expression noise (Figure S4C-D), which is consistent with the 
drug screening experimental results (Figure 1B) (4). 
However, under the detailed balance condition, neither synergy between AC 
and NE nor depression of Noise Suppressor (NS) on AC reactivating latent 
HIV can be possible (Figure 4). This contradicts the experimental data 
showing that NEs enhance AC’s inducing latent HIV reactivation and that NSs 
reduce AC’s reactivating latent HIV (Figure 1B) (4). It is because under the 
detailed balance condition, the probability 𝑃୭୬ of RNA polymerase binding to 
LTR (LTR-P and LTR*-P) (See Supplementary Section 2.1 and 2.5 for details) 
only depends on the equilibrium constants of each reaction, and NE or NS 
tunes the forward and backward rates simultaneously but keeps the 
equilibrium constant unvaried. This conclusion is not dependent on concrete 
models. It is a general physical and mathematical result. Hence it is not 
possible to build another even more complicated Detailed-Balanced model to 
overcome this obstacle.  
The above theory can be illustrated by our LTR-four-state model (Figure 3A, 
C, and Figure S2A, C) (See Supplementary Section 2.1,2.3 and 2.4 for 
details). Under the detailed balance condition, 𝑃୭୬ keeps the same when both 
NE (or NS) and AC are added to the system (𝛾 ≫ 1, 𝛼 ൌ 1 (or 𝛼 ൌ െ1)) 
compared to when only AC is added (𝛾 ≫ 1, 𝛼 ൌ 0) (Figure 4A; see 
Supplementary Section 2.5 for details). Thus, the Detailed-Balanced LTR-
four-state model predicts no synergy between NE and AC and predicts that 
NS does not suppress the AC’s function of increasing 𝑃୭୬ (Figure 4A), 
contradicting the experimentally observed synergy between AC and NE 
(Figure 1B) (4).  
We couple the Detailed-Balanced LTR-four-state model with Tat 
transactivation, and there is still no synergy between Noise Enhancer and 
Activator illustrated by the reactivation ratio of latent HIV (Figure 4B; see 
Supplementary Section 2.7 for details). Note that the reactivation ratio of HIV 
is calculated dynamically during a finite time starting from the latent state, 
which is different from the steady-state probability 𝑃୭୬. However, they are 
closely related to each other, since they both indicate the degree of 
reactivation for latent HIV.  
In addition, we calculate the mean duration time (MDT) of both the LTR-off 
states (LTR and LTR*) and the LTR-on states (LTR-P and LTR*-P) (See 
Supplementary Section 2.8 for details). The reciprocals of the MDTs 
calculated from the LTR-four-state model can be regarded as the effective 
transition rates in the reduced LTR-two-state model with only the LTR-off and 
LTR-on state. Then we find out that AC can shorten the MDT at LTR-off 
states (Figure S4E, Figure S4F), and that NE can lengthen the MDT at both 
LTR-on states and LTR-off states with their ratio fixed (Figure 4C-D, S5G-H). 
These results are consistent with the assumptions of the LTR-two-state model 
in the previous section. However, in this Detailed-Balanced model, the 
effective inhibiting effect quantity 𝑓୧୬୦ defined through the effective transition 
rates, always vanishes (Figure 4E; see Supplementary Section 2.9 for the 
exact definition of 𝑓୧୬୦). This confirms the LTR-two-state model predictions, 
that no synergy between AC and NE on reactivating latent HIV should be 
observed when 𝑓୧୬୦ ൌ 0. 
Hence, for Noise Enhancers synergize with ACs, the regulation of HIV gene 
expression must be a Non-Detailed-Balanced process with energy dissipation.  
The direction of the cycle flux caused by energy input in the Non-
Detailed-Balanced LTR-four-state model determines the synergy 
Inside a living cell, continuous energy consumption is necessary for executing 
different vital functions. We already know that systems with the drug synergy 
must be energy dissipative, but how energy input, i.e., breaking the detailed 
balance, influences the drug synergy remains poorly understood.  
We mainly investigate how the cycle flux direction and the energy input 
distribution, as the features of the non-equilibrium system, effect the synergy. 
Breaking the detailed balance is equivalent to having non-vanishing cycle 
fluxes. In our LTR-four-state model, the cycle fluxes can be either counter-
clockwise or clockwise. Energy input can be distributed on one or more 
reactions. Here, we first consider the case when energy input is only through 
one single reaction (Figure 5A; see Supplementary Section 2.2 and Table S2-
1 for details). In the real biological system, the energy input can be realized 
through ATP hydrolysis or other reversible covalent modification (44). 
We prove that the Non-Detailed-Balanced LTR-four-state model can produce 
the drug synergy between NE and AC on 𝑃୭୬, if and only if the direction of 
cycle flux is clockwise. Mathematical analysis (See Supplementary Section 
2.10 for details) and numerical simulations illustrate the same phenomenon. 
The model with counter-clockwise cycle flux predicts no synergy between NE 
and AC on 𝑃୭୬ or HIV latency reactivation, and no reduction of 𝑃୭୬ or latent 
HIV reactivation is observed when NS is added with AC (Figure 5B). On the 
other hand, with clockwise cycle flux, the model predicts 100% of NE can 
synergize with AC on 𝑃୭୬, and about 75% of NE synergize with AC on latent 
HIV reactivation (Figure 5C). 50% (4 out of 8) of the ways to break the 
detailed balance through a single reaction to produce a clockwise cyclic 
probability flux predicts significant synergy (൐ 5%) on 𝑃୭୬ between NE and AC 
(Figure 5C up panel), and that NS reduces 𝑃୭୬ with AC added. 25% (2 out of 
8, increasing transition rate from LTR*-P to LTR-P or reducing transition rate 
from LTR-P to LTR*-P) of the ways predicts significant synergy (൐ 5%) on 
reactivation of latent HIV between NE and AC (Figure 5C down panel), and 
that NS reduces AC-induced HIV latency reactivation. In the experiments, 
around 80% of the NSs reduce AC-induced HIV latency reactivation, while 
more than 64% of NEs have synergistic effects with AC on reactivating latent 
HIV (4). Hence the results of our model are consistent with the experimental 
fact that the majority of NEs amplify AC reactivating latent HIV, while the 
majority of NSs suppresses reactivation of latent HIV with AC added. Thus, 
the Non-Detailed-Balanced LTR-four-state model reveals a general 
mechanism of the synergy between NEs and ACs on the reactivation of latent 
HIV, instead of a particular mechanism of a specific NE. 
We also show that in the above cases producing significant drug synergy 
between AC and NE, the clockwise cyclic probability flux always promotes 
LTR turn on mainly through the LTR*-to-LTR*-P pathway strengthened by AC 
and turn off through the LTR-P-to-LTR pathway weakened directly by NE 
(Figure 5D-E). It explains why NE can further amply the HIV latency 
reactivation induced by AC, as long as the energy input provides clockwise 
cyclic probability flux. 
In addition, for the equilibrium system, the distribution of the dwell time at 
LTR-off states is predicted to be monotonically decreasing and convex (45) 
(Figure S10, solid black lines). The monotonicity or convexity can be 
maintained for the non-equilibrium system with a low magnitude of energy 
input (small disturbance from the equilibrium system) (Figure S10, dashed red 
line). However, as the magnitude of energy dissipation increases, the 
nonmonotonicity or concavity of the distribution of dwell time could appear, 
similar to the phenomenon of phase transition (Figure S10D, H, dotted red 
line, and solid red line). 
The LTR-four-state model with distributed energy input may achieve 
much stronger synergy than that with energy input only on a single 
reaction 
One possible strategy, through which strong synergy can be achieved, is to 
drive the LTR promoter to turn on mostly through the LTR-to-LTR*-to-LTR*-P 
pathway, whose rate can be significantly increased by AC, and to turn off 
mostly through the LTR*P-to-LTR-P-to-LTR pathway (Figure 5D-E), whose 
rate can be distinctly decreased by NE. This way, the promoter is more likely 
to transit to the state LTR-P rather than the state LTR* once it is at the state 
LTR*-P. Here, we build an EITST (Energy Input on the Two Specific 
Transition rates) LTR-four-state model, in which part of the energy input 
reduces the transition rate from LTR*-P to LTR* (𝛽ଶ) and the other part 
increases the transition rate from LTR*-P to LTR-P (𝛽ଵ) (Figure 6A; see 
Supplementary Section 2.2 for details), with the total energy fixed (𝛽ଵ ൅ 𝛽ଶ ൌ
𝛽).  
We find that there is an optimal energy input distribution (𝛽ଵ ൌ 1.8, 𝛽ଶ ൌ 8.2) 
for the system to perform the strongest synergy between AC and NE on 𝑃୭୬ 
(Figure 6B). The drug synergy on HIV latency reactivation dependent on the 
energy input distribution is qualitatively quite similar. (Figure 6C). Overall, the 
certain distributed energy input with 0 ൏ 𝛽ଵ ൏ 10 may achieve stronger 
synergy than that on only a single reaction (𝛽ଵ ൌ 0 or 𝛽ଵ ൌ 10). Without loss of 
generality, we set 𝛽ଵ ൌ 5, 𝛽ଶ ൌ 5 for the EITST LTR-four-state model, and all 
the following simulation results are based on this value. 
In such a Non-Detailed-Balanced model, simulation results of adding AC or 
NE alone with GFP present are consistent with the drug screening 
experimental data, that AC increases LTR mean expression level and NE 
increases LTR expression noise (Figure 6D-E, Figure 1B).  
The synergy between Noise Enhancer and Activator on both 𝑃୭୬ (Figure 6G) 
and HIV latency reactivation (Figure 6H) are observed and much stronger 
than the scenario where energy input is only on a single reaction. Noise 
Enhancer can increase the HIV latency reactivation from approximately 7% 
when Activator is already added to 13% when both are added (Figure 6H). 
These numbers are quite similar to the best cases observed in experiments 
with prostratin as AC (experimental data from Figure 3A in (4)).  And Noise 
suppressor reduces the AC-induced HIV latency reactivation from 7% to less 
than 1% (Figure 6H). This synergy between AC and NE on both 𝑃୭୬ and HIV 
latency reactivation is found to be positively correlated with the magnitude |𝛽| 
of the energy input, but will reach maximum (for 𝑃୭୬) and saturation (for HIV 
latency reactivation) when |𝛽| is getting sufficiently large (𝛽 ൐ 5) (Figure S6A-
B). In addition, the synergy is found to be positively correlated with the noise 
of NEs (Figure S6C), this is also consistent with the experimental data (Figure 
3B in (4)). 
We also calculate the mean duration time (MDT) of the LTR-off and LTR-on 
states. Different from the Detailed-Balanced situation, NEs can lengthen the 
MDT at the LTR-on states more significantly than lengthen the MDT at the 
LTR-off states (Figure 6F, Figure S7C-F). Further, the effective inhibiting 
parameter 𝑓୧୬୦ ൎ 1 ൐ 0 (See Supplementary Section 2.9 for the exact 
definition of this effective parameter) means that AC does inhibit NE’s function 
of reducing the transition rate from the LTR-off states to the LTR-on states 
(Figure 6F). These simulation results verified the conclusion we made in the 
LTR-two-state model, that NE can synergize with AC and NE on reactivating 
latent HIV only when 𝑓୧୬୦ ൐ 0. Now we know that AC’s inhibiting NE’s function 
of reducing effective 𝑘୭୬ is achieved by the clockwise cycle flux driven by the 
energy input. 
However, same as in the LTR-two-state model, Noise Enhancer can amplify 
Activator’s reactivating latent HIV only if 𝑘୳୬ୠ୧୬ୢ୮ (equivalent to 𝑘୭୤୤ in the 
LTR-two-state model) is greater than 10ିଶ (Figure S8A). To explain this 
necessary condition, we analyze the timescale of Tat transactivation 
dynamics and the timescale of LTR transitions. We find that it takes about 
𝜏଴ ൎ 20 hours on average for Tat transactivation and then LTR can maintain 
the activated state for a long time (Figure S8B-C). Therefore, if 𝑘୳୬ୠ୧୬ୢ୮ is very 
small compared to the time scale of 1/𝜏଴ , the duration time of LTR-on state 
without NE presented will be long enough for Tat transactivation with a large 
possibility, so further reducing  𝑘୳୬ୠ୧୬ୢ୮ by NE will have little effect (Figure 
S8B). Only when 𝑘୳୬ୠ୧୬ୢ୮ is not small compared to 1/𝜏଴, the duration time of 
LTR-on state without NE presented is typically not long enough for Tat 
transactivation. In this case, noise enhancer lengthening the duration time at 
the LTR-on state will provide Tat more time to reactivate latent HIV (Figure 
S8B), resulting in the drug synergy with Activator.   
Finally, to verify the model applicability, we use the same EITST model to 
explain other important previous experimental observations (Figure S3A-C) 
including Tat-transactivation-controlled HIV latency establishment operating 
autonomously from the host cellular state (31) and the bimodal distribution of 
phenotype bifurcation (10) (See supplementary Section 2.13 for parameter 
values). Also, in our EITST model, nonmonotonicity and concavity of the 
distribution of the dwell time are also observed with large magnitude of energy 
dissipation (Figure S10F). 
Discussion 
Retroviruses are mild at beginning infection. Most replicable retroviruses do 
not cause cytopathic effects, and infected cells hardly produce a defensive 
response to such viral replication. Animals rarely experience acute symptoms 
due to infection with retroviruses, but viremia occurs; the host immune 
responses reduce the production of the virus. The virus cannot be eradicated 
even though can be suppressed by the host's immune response. Therefore, 
low levels of viremia usually accompany the life of the host (46). As a typical 
example of the retrovirus, the long-lived latent HIV-1 are the main obstacles to 
a clinical cure (2). Recently, noise enhanced synergistic combinations of 
drugs (Activators and Noise Enhancers) were reported more effective than 
other reactivation cocktails on reactivating HIV latency (4). We here propose 
an LTR-four-state model with Tat transactivation (the cooperativity is only 
one) to reveal the mechanism of this synergy, produced by the combination of 
Activator and Noise Enhancer. By analysis and simulation of the model, we 
find that the drug synergy on HIV latency reactivation depends the distribution 
of energy input and the direction of cycle flux of the system. Such a proposed 
non-equilibrium mechanism should be useful for identifying new drug synergy 
or regulating the existing drug synergy in HIV and a diverse class of 
retroviruses infection therapies, most of which have latency states preventing 
from a complete cure. 
Design principle for specific biological functions have been extensively 
explored, such as reliable cell decisions (47), adaptation (48), robust and 
tunable biological oscillation (49), and dual function of adaptation and noise 
attenuation (50). Some of these functions, such as precise biochemical 
oscillations and accurate adaptation, were found crucially depending on the 
energy dissipation (26, 27). Here, we show that the drug synergy between NE 
and AC on reactivating HIV latency also essentially depends on the directional 
dissipated chemical energy on the HIV LTR-state transition. This non-
equilibrium property could also be used as a potential target for lentivirus 
latency reversal synergetic therapeutic interventions. The optimization 
principle of energy input distribution for the highest drug synergy might also 
apply to the network designing. 
Our LTR-four-state model is a minimal model in which the effects of AC and 
NE are distinguished. This LTR-four-state model can be expanded into a 
more detailed LTR-six-state model where the Tat positive feedback is 
modeled through Tat binding to LTR and forming two new states, LTR-P-Tat 
and LTR*-P-Tat as modeled in the previous study (31). In the LTR-six-state 
model, the same synergy can be predicted (Figure S9, Supplementary 
Section 2.4). Hence, our uncovered non-equilibrium mechanism of drug 
synergy is not dependent on the specific Tat positive feedback mechanism.  
The synergy that we studied here does not require cooperative binding 
between the two categories of drugs (AC and NE or NS), which is essentially 
different from the drug synergy based on classical equilibrium binding 
mechanism. It might be the reason why the tested drug synergies in vitro 
often fail in vivo. The nonequilibrium model proposed here provides a new 
perspective to understand the drug synergy mechanism.  
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FIGURE LEGENDS 
Figure 1. HIV-infected cell fates and biological function of biomolecules 
reactivating latent HIV.  
(A) Schematic of different fates of cells infected by HIV: HIV active replication, 
HIV proviral latency, and HIV latency reactivation (adapted from Figure 1A of 
(51)). 
(B) Diagram of experimentally screening Activator (AC) and Noise Enhancer 
(NE) (up) and experimental synergy test on the reactivation of latent HIV after 
adding AC or/and NE (down). In experiments, ACs and NEs were selected by 
to detecting the mean and noise of LTR expression using cells infected by the 
LTR-GFP vector. The synergy between ACs and NEs on HIV reactivation was 
tested using cells infected by full-length HIV with Tat transactivation. 
Untreated (grey bar) represents a control group. Adding Activator (green bar) 
increases LTR expression compared to the control group. Adding Noise 
Enhancer (magenta bar) increases LTR noise compared to the control group. 
Adding AC and NE simultaneously (red bar) has a strong synergy on HIV 
reactivation (increases Reactivation of latent HIV infected Cells). Adding AC 
and Noise Suppressors (NS, blue bar) has a depressing effect on HIV latency 
reactivation compared to adding AC only. (51) 
 
Figure 2. Two necessary conditions for drug synergy 
(A) Modified from Figure 3A of (31). The LTR-two-state model with Tat 
feedback to explain the effects of NE and AC molecules on HIV. LTR has two 
states, on and off, which convert to each other at the rate of 𝑘୭୬ and 𝑘୭୤୤; the 
LTR-on state transcribes HIV mRNA at a rate 𝑘୫, mRNA degrades at 𝑑୫ rate 
or translates to protein at a rate of 𝑘୘ୟ୲, and Tat degrades at rate 𝑑୘ୟ୲. NE 
decreases 𝑘୭୬ and 𝑘୭୤୤ with their ratio fixed; AC molecules will increase 𝑘୭୬; 
AC inhibits NE’s function on 𝑘୭୬ when added together as assumed in (51). Tat 
transactivate LTR through enhancing the transcriptional rate 𝑘୲୰ୟୱୟୡ୲. 
(B) The heat map of Reactivation across different values of LTR turning off 
rate 𝑘୭୤୤ and LTR turning on rate 𝑘୭୬. The green arrow corresponds to adding 
AC. Red arrow corresponds to adding NE only decreasing 𝑘୭୤୤ without 
changing 𝑘௢௡, i.e., AC inhibits NE’s function on 𝑘୭୬. Black arrow corresponds 
to adding NE decreasing 𝑘୭୤୤ and 𝑘୭୬ with their ratio fixed, i.e., AC does not 
inhibit NE decreasing 𝑘୭୬. (See Table S1-1 for parameter values) 
(C-D) The heat map of Synergy on Reactivation without AC’s inhibition on NE 
(𝑓୧୬୦ ൌ 0) and with AC’s complete inhibition on NE (𝑓୧୬୦ ൌ 1), respectively, 
across different values of 𝑘୭୤୤ and 𝑘୭୬ with AC added. The synergy is the 
reactivation with NE and AC added subtracting the reactivation with only AC 
added. (See Table S1-1 for parameter values) 
(E-G) The plots of synergy on reactivation changing with different 𝑓௜௡௛ values 
for small 𝑘୭୤୤, intermediate 𝑘୭୤୤, and large 𝑘୭୤୤, respectively. Red lines indicate 
adding NE and AC simultaneously; green lines indicate adding AC only; blue 
lines indicate adding NS and AC simultaneously. (See Table S1-1 and Table 
S1-2 for parameter values) 
 
Figure 3. The LTR-four-state model under the detailed balance condition 
and transcription/translation modules without/with Tat transactivation 
(A) Schematic of the LTR-four-state model with the Tat-feedback circuit. The 
LTR promoter is modeled to have four states: a transcriptional silence state 
(LTR state) extremely slowly binding RNAP polymerase or activation 
transcription factors such as NF-κB, an activated state (LTR*) such as LTR 
with NF-κB bond, a transcription-permissive state (LTR-P), a transcription-
permissive state with NF-κB bond (LTR*-P). 𝑘ୟୡ୲ is the rate for LTR binding 
NF-κB. 𝑘୳୬ୟୡ୲ is the rate for LTR unbinding NF-κB. 𝛾 models AC increases the 
rate for LTR binding NF-κB. 𝛾 ൌ 1 for untreated HIV infected cells, and 𝛾 ≫ 1 
for adding AC. 𝜔 is the attraction coefficient between NF-κB and RNAP, 𝜔 ൌ
10 (𝜔 ൐ 1 means NF-κB attracts RNAP); 𝑘ୠ୧୬ୢ୮ is the rate at which RNAP 
binds to LTR; 𝑘୳୬ୠ୧୬ୢ୮ is the rate at which RNAP unbinds from LTR; 𝛼 is the 
noise attenuation factor (𝛼 ൐ 0 corresponds to Noise Enhancer, and 𝛼 ൏ 0 
corresponds to Noise Suppressor). The parameter setting here is under the 
detailed balance condition. The case of breaking the detailed balance is in 
Figure 5 and Table S2-1. 
(B) Schematic of the LTR-four-state model coupled with the transcription and 
translation module without feedback. LTR-on states (red, including LTR-P 
state and LTR*-P state) transcribes mRNA at rate 𝑘୫; mRNA decays at rate 
𝑑୫ or can be translated at rate 𝑘୮ into GFP; GFP decays at rate 𝑑୮. 
(C) Schematic of the LTR-four-state model coupled with the transcription and 
translation module with the Tat-transactivation circuit. LTR-on states (red, 
including LTR-P state and LTR*-P state) transcribes mRNA at rate 𝑘୫; mRNA 
decays at rate 𝑑୫ or can be translated at rate 𝑘୘ୟ୲ into Tat; Tat decays at rate 
𝑑୘ୟ୲; Tat has positive feedback on 𝑘୫; Tat stabilizes the state of LTR-on state 
through negative feedback on 𝑘୳୬ୠ୧୬ୢ୮. 
 
Figure 4. No synergy is predicted under the detailed balance condition 
(A-B) Probability of LTR-on states (LTR-P state and LTR*-P state), 𝑃୭୬, and 
Reactivation ratio of Latent HIV, respectively, in the Detailed-Balanced LTR-
four-state model. Y-axis is the 𝑃୭୬ and the reactivation ratio value, 
respectively, and X-axis is the categories of different combinations of ACs and 
NEs/NSs. Untreated (grey bars) corresponds to 𝛾 ൌ 1, 𝛼 ൌ 0; adding only AC 
(green bars) corresponds to 𝛾 ≫ 1, 𝛼 ൌ 0; adding only NE (magenta bars) 
corresponds to 𝛾 ൌ 1, 𝛼 ൌ 1; adding NE and AC (red bars) corresponds to 
𝛾 ≫ 1, 𝛼 ൌ 1; adding NS and AC (blue bars) corresponds to 𝛾 ≫ 1, 𝛼 ൌ െ1. 
(B) We use Stochastic Simulation Algorithm (SSA) to calculate the 
reactivation ratio of the LTR-four-state model coupled with Tat feedback. 
Reactivation Ratio is the ratio of reactivated HIV trajectory number by time 
100h to all trajectory number, starting from latency state (LTR=1, all other 
species=0, simulated 5000 cells).  
(C-D) Mean Duration Time at LTR-off states and LTR-on states, respectively, 
under the detailed balance condition.  
(E) 𝑓୧୬୦, the degree of AC’s inhibition upon the reduction of 𝑘୭୬ induced by NE 
under the detailed balance condition. We first calculate the reciprocal of the 
Mean Duration Time as the transition rate between LTR-on and LTR-off 
states, 𝜆୭୬ and 𝜆୭୤୤, respectively. Then we calculate using the formula: 𝑓୧୬୦ ൌ
୪୬൫௞౥౤ሺሾேሿ,ሾ஺ሿሻ൯ି୪୬൫௞౥౤ሺ଴,ሾ஺ሿሻ൯
୪୬൫௞౥౜౜ሺ଴,ሾ஺ሿሻ൯ି୪୬൫௞౥౜౜ሺሾேሿ,ሾ஺ሿሻ൯ ൅ 1. (C-E) The red lines correspond to adding AC 
and NE (𝛼 ൐ 0); the cyan lines correspond to adding AC only (𝛼 ൌ 0); the blue 
lines correspond to adding AC and NS (𝛼 ൏ 0). (See Table S2-3 and Table 
S2-4 for parameter values.) 
 
Figure 5. The LTR-four-state model with energy input on a single transition 
produces synergy between AC and NE if and only if the system has 
clockwise cyclic probability flux  
(A) Schematic of the Non-Detailed-Balanced LTR-four-state model. Energy 
input can influence any single transition rate of the Detailed-Balanced LTR-
four-state model with the corresponding rate multiplying by 𝑒ఉ or 𝑒ିఉ. Such an 
energy input will cause clockwise (c.w.) cyclic probability flux or counter-
clockwise (c.c.w.) cyclic probability flux. 
(B-C) Probability of LTR-on states, 𝑃୭୬ (up panels), and Reactivation ratio of 
Latent HIV (down panels) calculated from the Non-Detailed-Balanced models 
with energy input on different single transitions causing a c.c.w. cyclic 
probability flux (B) or c.w. cyclic probability flux (C). R stands for LTR state; R* 
stands for LTR* state; P stands for LTR-P state; R*P stands for LTR*-P state. 
Each group of x-axis represents the Non-Detailed-Balanced model with the 
corresponding transition rate multiplying by 𝑒ఉ (𝛽 ൐ 0 for orange groups, 𝛽 ൏
0 for blue groups).  (See Table S2-1 for model details. See Table S2-3 and 
Table S2-4 for parameter values.)  
(D-E) The distributions of fluxes for LTR turning on (left panels) and turning off 
(right panels).  
(See Table S2-1 and Supplementary Section 2.5-7 for model details. See 
Table S2-3 and Table S2-4 for parameter values.) 
 
Figure 6. The LTR-four-state model with distributed energy input exhibit 
strong synergy between AC and NE 
(A) Schematic of the EITST model with distributed energy input (𝛽 ൌ 𝛽ଵ ൅
𝛽ଶ ൌ 10). The first part of the energy 𝛽ଵ increases the LTR*-P-to-LTR-P 
transition rate by multiplying 𝑒ఉభ, the other part of the energy 𝛽ଶ reduces the 
LTR*-P-to-LTR* transition rate by multiplying 𝑒ିఉమ. 
(B-C) The synergy on 𝑃୭୬ (B) and HIV latency reactivation (C) vary with 
energy distribution (𝛽ଵ ൅ 𝛽ଶ ൌ 𝛽 ൌ 10). (C) Each point is average of 250 
simulation experimental data points with 10000 cells simulated for each 
simulation experiment. Error bars show the Standard Deviation.  
(D-J) 𝛽ଵ ൌ 𝛽ଶ ൌ 5. 
(D-E) The mean and noise of GFP expression calculated from the EITST 
model without positive feedback. 
(F) 𝑓୧୬୦, the degree of AC’s inhibition upon the reduction of 𝑘୭୬ induced by NE 
of the EITST model. 
(G-H) Probability of LTR-on states (LTR-P state and LTR*-P state), 𝑃୭୬, and 
Reactivation ratio of Latent HIV, calculated from the EITST model. (See Table 
S2-1 for model details. See Table S2-3, S2-4, and S2-5 for parameter values.) 
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